800 Health Care

Junshi Biosciences' Toripalimab Combined with RemeGen's RC48 Approved for New Indication

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

399933

165519

159647

161726

<p>The Penghua CSI Chinese Medicine ETF rose by more than 1.8%, influenced by the opinions on the pricing mechanism for pharmaceuticals released by the General Office of the State Council. The opinion aims to regulate the prices of raw and auxiliary materials for medicines and promote the development of high-quality and high-priced Chinese medicinal materials. Institutional analysis suggests that Chinese medicine companies have low valuations and high dividend rates, and will benefit from policy support and market recovery in the future. The CSI Chinese Medicine Index rose by 2.04%, with many Chinese medicine stocks performing strongly. Overall, the state supports the development of traditional Chinese medicine, and the industry is expected to achieve high-quality growth</p>

腾讯新闻 - 财经

CITIC-Prudential CSI 800 Pharmaceuticals and Biotechnology Index Fund(LOF)-A

Penghua CSI Chinese Medicine ETF

China Merchants CNI BIOMEDICINE Index Fund-A

CONBA

Zhongheng Group

BUCHANG PHARMA

ZHONGSHENGYAOYE

YABAO PHARM.CORP

Yunnan Baiyao

ZZPZH

DEEJ

CR Sanjiu

JI LIN AO DONG

GYBYS

BAIYUNSHAN PH

YILING PHARMACEUTICAL

DRTG

TONG REN TANG

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

中证医疗

000933

159506

512170

159303

512010

159929

513060

560260

<p>The General Office of the State Council has issued an opinion to improve the price formation mechanism for centralized volume-based drug procurement, promote standardization and normalization of drug procurement, and expand channels for docking between pharmaceutical enterprises and medical institutions. The opinion emphasizes demand orientation and quality priority, aiming to form reasonable prices through fair competition while optimizing procurement rules to ensure drug quality and stable supply. Additionally, it strengthens policy coordination between medical insurance payment standards and procurement prices, ensuring that payment standards for drugs within the medical insurance catalog are based on the winning bid prices</p>

Wallstreetcn

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP CSI Medical Service ETF

Dacheng Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

GF Fund CSI Medical Service ETF

State Council Office: Improve the Price Formation Mechanism for Centralized Volume-Based Drug Procurement and Enhance Management of Listed Drug Prices

800 Health Care(399933.SZ)

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

State Council Office: Improve the Price Formation Mechanism for Centralized Volume-Based Drug Procurement and Enhance Management of Listed Drug Prices